COVID-19 Tracker & Statistics:
Duke University Dashboard (updated weekly) [here](#).
UNC Health Dashboard (updated daily) [here](#).
NC DPH Dashboard (updated daily) [here](#).
SC DPH Dashboard (updated daily) [here](#).
GA DPH Dashboard (updated weekly) [here](#).
VA DPH Dashboard (updated daily) [here](#).
WV DPH Dashboard (updated daily) [here](#).
FL DPH Dashboard (updated daily) [here](#).
Johns Hopkins Global Dashboard (updated daily) [here](#).

COVID-19 Guidance & Resources:
DICON website [here](#).
CDC website [here](#).

COVID-19 Vaccine Tracker:
NYT Vaccine Tracker [here](#).

COVID-19 Vaccine News:
- The Advisory Committee on Immunization Practices’ Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine — United States, 2020
- University of Michigan Survey of vaccine acceptance in older adults
- The CDC has posted all state vaccination plans

Current Status of Vaccine Data:
- Pfizer (mRNA, 2 doses 21 days apart)- FDA review date 12/10
  - EUA has been filed (anticipated turn around is 2 weeks)
  - Cold chain requirements: -70 (+/- 10-15 degrees)- good for 5 days in the refrigerator, Pfizer has developed a thermal shipper that will keep vaccine frozen on dry ice for 15 days (will need dry ice replenishment)
- Moderna (mRNA, 2 doses 28 days apart)- FDA review date 12/17
  - From NEJM 12/3: Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
  - Cold chain requirements- good under refrigeration for 30 days
- Astra Zeneca (adenovirus vector vaccine, initially studied as 2 doses)
  - November 23rd press release on efficacy

CDC:
There were multiple updates from CDC over the last week, two of the main updates being to the document Options to Reduce Quarantine for Contacts of Persons with SARS-CoV-2 Infection Using Symptom Monitoring and Diagnostic Testing and guidance on When to Quarantine.
Resources are available from the Centers for Disease Control and Prevention to respond to disruptions in STI clinical services, including guidance on STD treatment during the pandemic given shortages of azithromycin and approaches to prioritizing STI testing due to shortages of STI test kits and lab supplies.

FDA:
The FDA released a general update on December 1, 2020 outlining actions it will be taking in response to the COVID-19 pandemic.

The FDA also issued guidance on the use of dry heat to help support the single-user reuse of certain particulate filtering facepiece respirators (FFRs), such as N95 respirators, by healthcare personnel when there is a limited supply of respirators.

Interesting Literature for Infection Prevention:
- Increase in Hospital-Acquired Carbapenem-Resistant Acinetobacter baumannii Infection and Colonization in an Acute Care Hospital During a Surge in COVID-19 Admissions
- A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
- Outdoor Transmission of SARS-CoV-2 and Other Respiratory Viruses, a Systematic Review
- N95 respirator reuse during the COVID-19 pandemic: Healthcare worker perceptions and attitudes
- The Impact of COVID-19 Response on Central Line Associated Bloodstream Infections and Blood Culture Contamination Rates at a Tertiary Care Center in Greater Detroit Area
- Disproportionate Incidence of COVID-19 Infection, Hospitalizations, and Deaths Among Persons Identifying as Hispanic or Latino
- Increase in Hospital-Acquired Carbapenem-Resistant Acinetobacter baumannii Infection and Colonization in an Acute Care Hospital During a Surge in COVID-19 Admissions
- COVID-19 Outbreak Associated with a 10-Day Motorcycle Rally in a Neighboring State
- Trends in County-Level COVID-19 Incidence in Counties With and Without a Mask Mandate
- Racial disparities in COVID-19 mortality are driven by unequal infection risks
- The COVID-19 Pan-Syndemic – will we ever learn?
- Improving surveillance estimates of COVID-19 incidence in the United States
- Characteristics of Adults aged 18–49 Years without Underlying Conditions Hospitalized with Laboratory-Confirmed COVID-19 in the United States

Do you have a suggestion for a new FAQ, position statement, or newsletter? Reach out here or discuss with your DICON IP liaison.